📄 Bridge Financing or Priced Equity Round?

🎉 Happy Friday, funds family!

When a company raises capital, one of the first and most significant decisions it has to make is whether to fundraise through a bridge financing instrument (usually a SAFE or, less commonly now, convertible note) or through a priced equity round (“Series Seed,” “Series A” and so forth). It’s an important question for companies and investors, because the decision affects valuation, dilution, governance, tax treatment, and potentially the company’s ability to raise additional capital down the line.

The short answer is: bridge financing is usually faster, cheaper, and lighter touch, which makes it a good fit for [very] early-stage companies that need to move quickly and/or aren’t ready to set a valuation.

Priced equity financing is meaningfully more substantive and expensive, but it sets a clear valuation of the company, defines investor rights and control, and may also have some additional tax benefits (which warrants a whole separate conversation, frankly).

➡️ What is the difference between bridge financings and priced rounds?

Bridge financing instruments are typically designed to convert into equity later, usually at the next priced equity round (or, less typically, an exit). The investor gives the company money now in exchange for the right to receive shares later, often at a discount to the future round’s price and/or subject to a valuation cap. So there are no shares issued today, no board seats or extensive investor rights granted today, and no clear valuation set as of today.

Priced equity financings, by contrast, issue actual shares (preferred stock) at closing, with a defined valuation (usually post-money valuation, which includes the cash coming in), defined governance rights, and full transaction/financing documents (i.e., stock purchase agreement, certificate of incorporation/charter, investors’ rights agreement, voting agreement, and right of first refusal/co-sale agreement).

➡️ When does bridge financing make sense?

Bridge financing tends to be the better fit when:

• The company needs capital quickly (e.g., to extend runway right away).

• The parties cannot agree on a valuation as of now (or the valuation would be unfavorable for the company).

• The company expects a priced round in the near future.

• The round is small, and the cost/time of full equity documents is disproportionate.

• The investor base is primarily friends and family, angels, or early venture checks.

The trade-off is that the company defers valuation to a later round, which means uncertainty (for all stakeholders) about the ultimate dilution.

➡️ When does a priced equity round make sense?

Priced equity rounds tend to be the better fit when:

• The company is raising a meaningful amount of institutional capital.

• The parties can agree on a clearer valuation.

• Investors want defined governance rights (board seats, protective provisions, information rights).

• The company wants to clean up the “cap table” before scaling and wants dilution to be clearly defined.

• The company wants to start the QSBS clock for shareholders/investors (though tax folks do often agree that a SAFE can start the QSBS holding period – see below).

This format gives both sides certainty, but it also costs more in legal fees and takes longer to close.

🏦 Tax corner: The 💰️ QSBS point matters for the bridge versus equity decision because the QSBS holding period generally starts when the stock is actually issued, not when the convertible note is signed. So a convertible note that doesn’t convert until two years later means the holder doesn’t start the five-year clock until conversion. If the company is sold soon after, the investor may miss the QSBS exclusion entirely. While it is not determinative or perfectly guided, many tax advisors do take the position that a SAFE, in contrast to convertible notes, does in fact constitute equity for the purposes of starting the QSBS holding period (again, this should be taken with a grain of salt and analyzed with independent tax advisors on the risk).

➡️ The practical takeaway

For the company:

1. Use bridge financing for speed and simplicity, but understand that the valuation and dilution conversation is being deferred, not avoided.

2. Move to a priced equity round when the round size, investor profile, or tax planning calls for it.

3. Keep the cap table clean and track every SAFE and note so that the conversion math at the next round is not a surprise.

For the investor:

1. Understand which instrument starts the QSBS clock and when, and factor that into the holding period analysis; understand the tax implications.

2. Review the conversion mechanics carefully (caps, discounts, MFN, pro rata) before signing.

3. For meaningful checks, push for a priced round if the company can support it, especially if specified economic or governance rights are important.

4. Don’t assume that a SAFE or note is harmless because it is short – the conversion can drive significant dilution at the next round.

Thanks for reading, everyone!

Have a great weekend! 🙌

⚠️ Note: This newsletter is for informational purposes only and nothing should be considered legal advice. For that, hire a lawyer! I am a lawyer, but not your lawyer (unless I actually am your lawyer because you’ve signed an engagement letter and we’re working together). This may be considered attorney advertising.